You are here

clinical trials

ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint

ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint

BioSpace

clinical trials

mirvetuximab soravtansine

Flag link:

Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way forward

Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way forward

Endpoints

clinical trials

Flag link:

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Pharmaforum

clinical trials

Flag link:

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

Endpoints

pancreatic cancer

clinical trials

BRCA-mutated prostate cancer

Flag link:

Can Roche’s little tech startup help the FDA change clinical trials?

Can Roche’s little tech startup help the FDA change clinical trials?

Stat

clinical trials

Flatiron Health

Flag link:

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

Endpoints

clinical trials

Flag link:

Intercept stock drop reflects the high bar set for NASH drugs

Intercept stock drop reflects the high bar set for NASH drugs

BioPharma Dive

Intercept Pharma

clinical trials

Flag link:

40 Sites Across The Country To Test New Alzheimer's Drug

40 Sites Across The Country To Test New Alzheimer's Drug

Forbes

clinical trials

Alzheimer's disease

Flag link:

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Endpoints

clinical trials

Flag link:

Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment

Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment

BioSpace

Intercept Pharmaceuticals

obeticholic acid

clinical trials

Flag link:

Higher dose of Pfizer-Lilly drug helps reduce back pain in study

Higher dose of Pfizer-Lilly drug helps reduce back pain in study

Yahoo/Reuters

chronic low back pain

clinical trials

opioid alternatives

Flag link:

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Pharmaceutical Business Review

Boehringer Ingelheim

type 2 diabetes

clinical trials

Flag link:

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

BioPharma Dive

prostate cancer

clinical trials

Flag link:

Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada

Boehringer Ingelheim and IBM link up for blockchain-powered clinical trials in Canada

Fierce Biotech

Boehringer Ingelheim

clinical trials

Flag link:

Interview: Clinical Trial Transparency Is Improving, Particularly Among Larger Companies

Interview: Clinical Trial Transparency Is Improving, Particularly Among Larger Companies

BioSpace

clinical trials

clinical trial transparency

Flag link:

Asco-GU – Bristol’s renal cancer lead looks to be short-lived

Asco-GU – Bristol’s renal cancer lead looks to be short-lived

EP Vantage

renal cell carcinoma

Bristol-Myers Squibb

clinical trials

Flag link:

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

Endpoints

Gilead Sciences

clinical trials

Flag link:

Here's Why Sage Therapeutics Gained 48.9% in January

Here's Why Sage Therapeutics Gained 48.9% in January

Motley Fool

SAGE Therapeutics

postpartum depression

clinical trials

Flag link:

Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Bloomberg

Sangamo BioSciences

clinical trials

Flag link:

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

Endpoints

Solid Biosciences

clinical trials

Duchenne Muscular Dystrophy

Flag link:

Pages